<\/p>\n
Gravitor SR<\/strong> je peror\u00e1ln\u00ed sustained-release tablet<\/strong> (typically 180 mg, 8–12 hour release) containing pyridostigmine bromide<\/strong> (180 mg) — an acetylcholinesterase inhibitor used to treat myasthenia gravis<\/strong>. Action duration: 8–12 hours<\/strong> per dose. The SR formulation is preferred for nocturnal weakness and morning ptosis<\/strong>; one tablet at bedtime maintains therapeutic levels through the night. It works by blocking the breakdown of acetylcholine at the neuromuscular junction, restoring muscle strength in patients whose acetylcholine receptors are blocked by autoantibodies. Adult dosing in myasthenia gravis: 30–120 mg every 4–6 hours<\/strong> for the immediate-release form (typical 60 mg three to five times daily); 180 mg every 12–24 hours for the sustained-release form. Take 30–45 minutes before meals if dysphagia is the dominant symptom. Common side effects: abdominal cramps, diarrhoea, nausea, sweating, increased salivation, miosis (small pupils), muscle twitching. Watch for cholinergic crisis<\/strong> — over-dose can mimic myasthenic crisis itself; the edrophonium or ice-pack test can distinguish.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Gravitor SR is an oral pyridostigmine bromide sustained-release tablet<\/strong> (typically 180 mg, 8–12 hour release) available in 180 mg. Pyridostigmine is a quaternary-ammonium reversible acetylcholinesterase inhibitor<\/strong> introduced in 1955 and one of the cornerstones of myasthenia gravis treatment ever since. Because the molecule is a permanently charged quaternary ammonium, it does not cross the blood-brain barrier — central effects are minimal compared with tertiary-amine cholinesterase inhibitors used for Alzheimer’s dementia.<\/p>\n The sustained-release form (Mestinon Timespan® \/ Gravitor SR SR) is designed to provide an 8–12-hour release window, primarily used at bedtime to cover nocturnal weakness and prevent morning ptosis or dysphagia<\/strong>. It is ne<\/em> a substitute for daytime immediate-release dosing in moderate-severe disease — the dose-by-dose adjustability of the immediate-release form is the standard backbone of therapy.<\/p>\n Gravitor SR is supplied by a WHO-GMP certified manufacturer and is bioequivalent to originator-brand pyridostigmine (Mestinon®).<\/p>\n In myasthenia gravis, autoantibodies (most commonly anti-acetylcholine-receptor antibodies, sometimes anti-MuSK) reduce the number of functional acetylcholine receptors at the neuromuscular junction. The signal from motor nerve to muscle becomes inefficient and muscles fatigue rapidly — the cardinal feature of the disease.<\/p>\n Pyridostigmine reversibly inhibits acetylcholinesterase<\/strong>, the enzyme that breaks down acetylcholine in the synaptic cleft. With less enzyme activity, acetylcholine persists longer and reaches more receptors, producing a stronger signal at the remaining functional acetylcholine receptors. The clinical result is improved muscle strength — particularly for ptosis, dysphagia, dysarthria and limb fatigue.<\/p>\n Pyridostigmine is symptomatic, not disease-modifying<\/strong>. It does not affect the underlying autoimmune process. Disease-modifying therapy (corticosteroids, azathioprine, mycophenolate, rituximab, eculizumab, efgartigimod, thymectomy) is needed to control disease activity in moderate-severe cases.<\/p>\n Pyridostigmine is ne<\/strong> first-line for: Alzheimer’s dementia (use donepezil, rivastigmine, galantamine), Parkinson’s disease, or as a routine cognitive enhancer.<\/p>\n Gravitor SR strength: 180 mg<\/strong>.<\/p>\n Standard adult dosing in myasthenia gravis:<\/strong><\/p>\n Common (often dose-related — cholinergic side effects):<\/strong><\/p>\n M\u00e9n\u011b \u010dast\u00e9, ale d\u016fle\u017eit\u00e9:<\/strong><\/p>\n Vz\u00e1cn\u00e9, ale vy\u017eaduje neodkladnou p\u00e9\u010di:<\/strong><\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
What Is Gravitor SR?<\/h2>\n
How Does Gravitor SR Work?<\/h2>\n
Pou\u017eit\u00ed a indikace<\/h2>\n
\n
Gravitor SR Dosage and How to Take<\/h2>\n
\n
How to Take Gravitor SR Properly<\/h3>\n
\n
Side Effects of Gravitor SR<\/h2>\n
\n
\n
\n
Varov\u00e1n\u00ed a preventivn\u00ed opat\u0159en\u00ed \u2014 KRITICK\u00c9<\/h2>\n
\n
Contraindications — Who Should NOT Take Gravitor SR<\/h2>\n
\n
Interakce s l\u00e9\u010divy<\/h2>\n